Multitarget-directed ligands: innovative chemical probes and therapeutic tools against Alzheimer's disease.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Current Topics in Medicinal Chemistry

• Publication date

  2011-10-31

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/156802611798184373PMID 22039879
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs

  2011cited by this paper
• Novel anti-Alzheimer’s dimer bis(7)-Cognitin: Cellular and molecular mechanisms of neuroprotection through multiple targets

  2011cited by this paper
• Memoquin: A multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer’s disease

  2011cited by this paper
• Multifunctional drugs as neurotherapeutics

  2011cited by this paper
• Alzheimer's disease.

  2010cited by this paper
• Alzheimer's disease drug discovery: Abeta and beyond.

  2010cited by this paper
• Pharmacology. The puzzling rise and fall of a dark-horse Alzheimer's drug.

  2010cited by this paper
• Strategies for the Inhibition of Protein Aggregation in Human Diseases

  2010cited by this paper
• The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action.

  2010cited by this paper
• Bis(7)‐tacrine Derivatives as Multitarget‐Directed Ligands: Focus on Anticholinesterase and Antiamyloid Activities

  2010cited by this paper
• Minding metals: tailoring multifunctional chelating agents for neurodegenerative disease.

  2010cited by this paper
• Alzheimer's disease: clinical trials and drug development

  2010cited by this paper
• Why Pleiotropic Interventions are Needed for Alzheimer's Disease

  2010cited by this paper
• Tacrine derivatives and Alzheimer's disease.

  2010cited by this paper
• Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the CSF of patients with Alzheimer’s disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process

  2010cited by this paper
• MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond.

  2009cited by this paper
• Lessons from 60 years of pharmaceutical innovation

  2009cited by this paper
• Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks.

  2009cited by this paper
• Discontinued drugs 2007: central and peripheral nervous system drugs.

  2009cited by this paper
• Alzheimer's disease: from pathology to therapeutic approaches.

  2009cited by this paper
• Altered redox balance in disease: Can we change the new equilibria?

  2009cited by this paper
• Designing multiple ligands - medicinal chemistry strategies and challenges.

  2009cited by this paper
• Small Molecule Protein–Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles

  2009cited by this paper
• Promising multifunctional anti-Alzheimer's dimer bis(7)-Cognitin acting as an activator of protein kinase C regulates activities of alpha-secretase and BACE-1 concurrently.

  2009cited by this paper
• Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase.

  2009cited by this paper
• Disease-Modifying Approach to the Treatment of Alzheimer’s Disease

  2009cited by this paper
• A gorge-spanning, high-affinity cholinesterase inhibitor to explore beta-amyloid plaques.

  2009cited by this paper
• Cell biology, regulation and inhibition of β‐secretase (BACE‐1)

  2009cited by this paper
• Alzheimer's disease drug development and the problem of the blood‐brain barrier

  2009cited by this paper
• Reassessing the amyloid cascade hypothesis of Alzheimer's disease.

  2009cited by this paper
• Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies.

  2009cited by this paper
• Alzheimer's disease: new approaches to drug discovery.

  2009cited by this paper
• Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.

  2009cited by this paper
• Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush.

  2008cited by this paper
• Amyloid–cholinesterase interactions

  2008cited by this paper
• Evidence of Oxidative Stress in Alzheimer's Disease Brain and Antioxidant Therapy

  2008cited by this paper
• Oxidative stress triggers the amyloidogenic pathway in human vascular smooth muscle cells.

  2008cited by this paper
• Portal to Alzheimer's disease

  2008cited by this paper
• Why Do So Many Drugs for Alzheimer's Disease Fail in Development? Time for New Methods and New Practices?

  2008cited by this paper
• From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease.

  2008cited by this paper
• Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease.

  2008cited by this paper
• Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds.

  2008cited by this paper
• Evaluation of Coenzyme Q as an Antioxidant Strategy for Alzheimer's Disease

  2008cited by this paper
• Multi-target-directed ligands to combat neurodegenerative diseases.

  2008cited by this paper
• Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease.

  2008cited by this paper
• Promising anti-Alzheimer's dimer bis(7)-tacrine reduces beta-amyloid generation by directly inhibiting BACE-1 activity.

  2008cited by this paper
• The Effects and Mechanisms of Mitochondrial Nutrient α-Lipoic Acid on Improving Age-Associated Mitochondrial and Cognitive Dysfunction: An Overview

  2007cited by this paper
• Causes of oxidative stress in Alzheimer disease

  2007cited by this paper
• Fragments, network biology and designing multiple ligands.

  2007cited by this paper
• The search for drug leads targeted to the beta-secretase: an example of the roles of computer assisted approaches in drug discovery.

  2007cited by this paper
• Mitochondrial respiratory inhibition and oxidative stress elevate β-secretase (BACE1) proteins and activity in vivo in the rat retina

  2007cited by this paper
• Insight Into the Kinetic of Amyloid β (1–42) Peptide Self‐Aggregation: Elucidation of Inhibitors’ Mechanism of Action

  2007cited by this paper
• Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.

  2007cited by this paper
• Structure–activity Relationships of Amyloid Beta‐aggregation Inhibitors Based on Curcumin: Influence of Linker Length and Flexibility

  2007cited by this paper
• Polyfluorinated bis-styrylbenzene beta-amyloid plaque binding ligands.

  2007cited by this paper
• Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.

  2007cited by this paper
• Congo red and protein aggregation in neurodegenerative diseases.

  2007cited by this paper
• Lipoic acid as a novel treatment for Alzheimer's disease and related dementias.

  2007cited by this paper
• Targeting acetylcholinesterase to treat neurodegeneration

  2007cited by this paper
• Alpha-lipoic acid exhibits anti-amyloidogenicity for beta-amyloid fibrils in vitro.

  2006cited by this paper
• Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal.

  2006cited by this paper
• Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors.

  2006cited by this paper
• Preformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitro.

  2005cited by this paper
• Rational approach to discover multipotent anti-Alzheimer drugs.

  2005cited by this paper
• Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease.

  2005cited by this paper
• Peripheral biomarkers of oxidative damage in Alzheimer's disease: the road ahead.

  2005cited by this paper
• Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology.

  2005cited by this paper
• Oxidative stress mechanisms and potential therapeutics in Alzheimer disease

  2005cited by this paper
• From magic bullets to designed multiple ligands.

  2004cited by this paper
• Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer's disease.

  2004cited by this paper
• beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies.

  2003cited by this paper
• Causes and consequences of oxidative stress in Alzheimer's disease.

  2002cited by this paper
• Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide.

  2001cited by this paper
• Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone.

  1999cited by this paper
• Quinone reductase (NQO1), a sensitive redox indicator, is increased in Alzheimer's disease.

  1999cited by this paper
• Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease.

  1998cited by this paper
• Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone).

  1998cited by this paper
• Highly Potent, Selective, and Low Cost Bis-tetrahydroaminacrine Inhibitors of Acetylcholinesterase

  1996cited by this paper
• Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme.

  1996cited by this paper
• Alzheimer's disease: the amyloid cascade hypothesis.

  1992cited by this paper

• Special Issue “Advances in Drug Discovery and Synthesis”

  2025cites this paper
• Lipoic acid scaffold applications in the design of multitarget-directed ligands against Alzheimer's disease.

  2025cites this paper
• Design, synthesis, and biological evaluation of novel N-Benzyl piperidine derivatives as potent HDAC/AChE inhibitors for Alzheimer's disease.

  2023cites this paper
• A Novel Donepezil–Caffeic Acid Hybrid: Synthesis, Biological Evaluation, and Molecular Docking Studies

  2023cites this paper
• Benzophenone Derivatives with Histamine H3 Receptor Affinity and Cholinesterase Inhibitory Potency as Multitarget-Directed Ligands for Possible Therapy of Alzheimer’s Disease

  2022cites this paper
• An overview on the synthesis of carbohydrate-based molecules with biological activity related to neurodegenerative diseases.

  2021cites this paper
• Design Strategies, Chemistry and Therapeutic Insights of Multi-target Directed Ligands as Antidepressant Agents

  2021cites this paper
• Preface: Cholinergic mechanisms

  2021cites this paper
• p-Benzoquinone a privileged scaffold of pharmacological significance: A review.

  2020cites this paper
• Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors.

  2019cites this paper
• Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).

  2019cites this paper
• Diversity‐Oriented Synthesis of Complex Pyrrole‐Based Architectures from Very Simple Starting Materials

  2019cites this paper
• Overview of novel multifunctional agents based on conjugates of γ-carbolines, carbazoles, tetrahydrocarbazoles, phenothiazines, and aminoadamantanes for treatment of Alzheimer's disease.

  2019cites this paper
• In vitro Anti-cholinesterase and Anti-oxidant Activity of Three Standardised Polyherbal Products Used for Memory Enhancing in Ethnomedicine of South-East Nigeria

  2018cites this paper
• Influence of the γ-carboline and carbazole pharmacophore moieties on anticholinesterase and antiradical activity of multifunctional agents for the treatment of neurodegenerative diseases

  2018cites this paper
• The efficacy of butylphthalide soft capsules combined with donepezil tablet in patients with alzheimer disease and its effect onSerum A beta, GSH-Px and SOD

  2018cites this paper
• Therapeutic Approaches to Prion Diseases.

  2017cites this paper
• Synthesis of new N-(pyridin-3-ylmethyl)-2-aminothiazoline derivatives possessing anticholinesterase and antiradical activity as potential multifunctional agents for the treatment of neurodegenerative diseases

  2017cites this paper
• Focused design of polypharmacophoric neuroprotective compounds: Conjugates of γ-carbolines with carbazole derivatives and tetrahydrocarbazole

  2017cites this paper
• Synthesis and application of β-carbolines as novel multi-functional anti-Alzheimer's disease agents.

  2017cites this paper
• Medicinal Chemistry of Hybrids for Neurodegenerative Diseases

  2017cites this paper
• The Use of Stilbene Scaffold in Medicinal Chemistry and Multi- Target Drug Design.

  2016cites this paper
• Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as multi-targeted compounds against Alzheimer's disease.

  2016cites this paper
• 1,2,4-Thiadiazoles as promising multifunctional agents for treatment of neurodegenerative diseases

  2016cites this paper
• Aβ regulation-based multitarget strategy for drug discovery against Alzheimer’s disease

  2015cites this paper
• From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer's Disease.

  2015cites this paper
• Sulfonamides as multifunctional agents for Alzheimer's disease.

  2015cites this paper
• Synthesis of New Lipoic Acid Conjugates and Evaluation of Their Free Radical Scavenging and Neuroprotective Activities

  2014cites this paper
• Multi-target Design Strategies in the Context of Alzheimer’s Disease: Acetylcholinesterase Inhibition and NMDA Receptor Antagonism as the Driving Forces

  2014cites this paper
• Indole alkaloids and semisynthetic indole derivatives as multifunctional scaffolds aiming the inhibition of enzymes related to neurodegenerative diseases--a focus on Psychotria L. Genus.

  2014cites this paper
• Dibenzo[1,4,5]thiadiazepine: a hardly-known heterocyclic system with neuroprotective properties of potential usefulness in the treatment of neurodegenerative diseases.

  2014cites this paper
• Two diseases, one approach: multitarget drug discovery in Alzheimer's and neglected tropical diseases

  2014cites this paper
• Pharmacological Characterization of Memoquin, a Multi-Target Compound for the Treatment of Alzheimer's Disease

  2013cites this paper
• Development of a neuroprotective antioxidant by a mix-and-match strategy -

  2013cites this paper
• Discovery of alkenylboronic acids as neuroprotective agents affecting multiple biological targets involved in Alzheimer's disease.

  2013cites this paper
• The multifactorial nature of Alzheimer's disease for developing potential therapeutics.

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes

  2013cites this paper
• Synthesis, kinetic studies and molecular modeling of novel tacrine dimers as cholinesterase inhibitors.

  2013cites this paper
• Multifunctional tacrine derivatives in Alzheimer's disease.

  2013cites this paper
• The Bivalent Ligand Approach as a Tool for Improving the in vitro Anti‐Alzheimer Multitarget Profile of Dimebon

  2013cites this paper
• Design of new drugs for the treatment of Alzheimer's disease based on tacrine structure.

  2013cites this paper
• In Silico Design of Inhibitors for -Secretase: Implications for Alzheimer's Disease

  2013cites this paper
• Design, synthesis and pharmacological evaluation of novel tacrine-caffeic acid hybrids as multi-targeted compounds against Alzheimer's disease.

  2012cites this paper